Abstract:BACKGROUND:High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). OBJECTIVES:We aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH. METHODS:We retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort. RESULTS:HDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34-57 mg/dl; PAH: 35.3, 29-39 mg/dl; Control: 49, 40-60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity. CONCLUSIONS:HDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH.

Abnormal Levels of Apolipoprotein A-I in Chronic Thromboembolic Pulmonary Hypertension

Plasma Levels of High Density Lipoprotein Cholesterol and Outcomes in Chronic Thromboembolic Pulmonary Hypertension.

Impact of Reduced Apolipoprotein A-I Levels on Pulmonary Arterial Hypertension.

Abstract: S5-17 APOLIPOPROTEIN AV IS A METABOLIC BIOMARKER LINKING INSULIN RESISTANCE WITH HYPERTRIGLYCERIDEMIA

Apolipoprotein A1 Is Associated with Pulmonary Vascular Resistance and Adverse Clinical Outcomes in Patients with Pulmonary hypertension secondary to Heart Failure

ANALYSIS OF T CELL IMMUNE FUNCTION OF 16 PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome.

Decreased Plasma Apolipoprotein A-Iv Levels in Patients with Acute Coronary Syndrome

Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients

Elevated Plasma Apolipoprotein AV in Acute Coronary Syndrome is Positively Correlated with Triglyceride and C-reactive Protein.

E0597 Serum HDL-C Levels Correlated with the Haemodynamic and Severity in Patients with Idiopathic Pulmonary Arterial Hypertension

Abstract 53: An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma

Association of Apolipoprotein A1, High Density Lipoprotein Cholesterol, and Their Ratio with Inflammatory Marker in Chinese Adults with Coronary Artery Disease

Plasma monomeric ApoA1 and high‐density lipoprotein bound ApoA1 are markedly decreased and associated with low levels of lipophilic antioxidants in sickle cell disease: A potential new pathway for therapy

APOA1 Level is Negatively Correlated with the Severity of COVID-19

Relationship Between Apolipoproteins and the Alteration of HDL Subclasses in Hyperlipidemic Subjects.

Circulating Apo B to A1 Ratio Reflects the Progression of Chronic Heart Failure with Different Etiologies

[Increased Serum Apolipoprotein A5 in Patients with Acute Coronary Syndrome].

Prevalence of Antiphospholipid (apl) Antibodies among Patients with Chronic Thromboembolic Pulmonary Hypertension: a Systematic Review and Meta-Analysis

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

Atherogenic index of plasma is associated with epicardial adipose tissue volume assessed on coronary computed tomography angiography